Trial Profile
A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Folate-fluorescein isothiocyanate conjugate (Primary)
- Indications Pituitary adenoma
- Focus Diagnostic use
- Acronyms OTL38 study
- 02 Aug 2019 Status changed from active, no longer recruiting to discontinued.
- 29 Jun 2018 Planned End Date changed from 1 Dec 2020 to 1 Sep 2020.
- 11 Jun 2017 Status changed from recruiting to active, no longer recruiting.